Completed PHASE3 INTERVENTIONAL 3-arm NCT00633932

Reflux Esophagitis Phase III Study (Initial Treatment)

A Multicentre, Randomised, Double-blind, Parallel-group, Comparative Study to Compare the Efficacy and Safety of Esomeprazole 20 mg and 40 mg Once Daily Oral Administration With Omeprazole 20 mg Once Daily Oral Administration in Patients With Reflux Esophagitis

Sponsor: AstraZeneca

Conditions Reflux Esophagitis

Interventions Esomeprazole Omeprazole

Updated 7 times since 2017 Last updated: Dec 2, 2010 Started: Dec 31, 2007 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00633932, this PHASE3 trial focuses on Reflux Esophagitis and remains completed. Sponsored by AstraZeneca, it has been updated 7 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adachi City, Japan , Akita, Japan , Fujiidera, Japan , Fujisawa, Japan , Fukuoka, Japan , Gifu, Japan , Hachiōji, Japan , Hitachi, Japan , Kashiwa, Japan , Kawasaki, Japan and 31 more locations